DOI: 10.1002/ame2.12347
Comparing the efficacy and safety of low,medium,and high dosages of selexipag for treating pulmonary hypertension:A systematic review and meta-analysis
Shang Wang1
Yi Yan2
Jian Zhang3
Ping Yuan1
Ci-Jun Luo1
Hong-Ling Qiu1
Hui-Ting Li1
Jian Xu1
Lan Wang1
Tian-Lan Li4
Rong Jiang1
1.Department of Cardio-Pulmonary Circulation,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai,China2.Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease,Shanghai Children's Medical Center,National Children's Medical Center,Shanghai Jiaotong University School of Medicine,Shanghai,China3.Department of Respiratory and Critical Care Medicine,The 416 Hospital of Nuclear Industry,The Second Affiliated Hospital of Chengdu Medical College,Chengdu,China4.Department of Hematology,The Affiliated Hospital of Qingdao University,Qingdao,China
摘要：Background:The maintenance dosage of selexipag is categorized as low,medium or high.In order to assess the efficacy and safety of different dosages of selexipag for the risk stratification of pulmonary arterial hypertension(PAH),we performed a sys-tematic review and meta-analysis.
Methods:Studies assessing PAH risk stratification indices,such as the World Health Organization functional class(WHO-FC),six-minute walk distance(6MWD),N-terminal pro-B-type natriuretic peptide(NT-proBNP)level,right atrial pressure(RAP),cardiac index(CI)and mixed venous oxygen saturation(SvO 2),were included.
Results:Thirteen studies were included.Selexipag led to improvements in the 6MWD(MD:24.20 m,95%CI:10.74-37.67),NT-proBNP(SMD:-0.41,95%CI:-0.79-0.04),CI(MD:0.47 L/min/m 2,95%CI:0.17-0.77)and WHO-FC(OR:0.564,95%CI:0.457-0.697).Subgroup analysis demonstrated that all three dosages improved the 6MWD.A moderate dosage led to improvements in the CI(MD:0.30 L/min/m 2,95%CI:0.15-0.46)and WHO-FC(OR:0.589,95%CI:0.376-0.922).Within 6 months of treatment,only the WHO-FC and CI were significantly improved(OR:0.614,95%CI:0.380-0.993;MD:0.30 L/min/m 2,95%CI:0.16-0.45,respectively).More than 6 months of treatment significantly improved the 6MWD,WHO-FC and NT-proBNP(MD:40.87 m,95%CI:10.97-70.77;OR:0.557,95%CI:0.440-0.705;SMD:-0.61,95%CI:-1.17-0.05,respectively).
Conclusions:Low,medium,and high dosages of selexipag all exhibited good effects.When treatment lasted for more than 6 months,selexipag exerted obvious effects,even in the low-dosage group.This finding is important for guiding individualized treatments.
机标关键词：meta-analysishypertensionselexipagreviewsafetyhighcomparingdosages
论文发表日期：2024-02-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：15( 56-70 )
英文信息